RT Journal Article
T1 Differences in Nutritional Status and Inflammatory Biomarkers between Female and Male Patients with Bronchiectasis: A Large-Cohort Study
A1 Wang, Xuejie
A1 Villa, Carmen
A1 Dobarganes, Yadira
A1 Olveira, Casilda
A1 Girón, Rosa
A1 García Clemente, Marta
A1 Maíz, Luis
A1 Sibila, Oriol
A1 Golpe, Rafael
A1 Menéndez, Rosario
A1 Rodríguez López, Juan Pedro
A1 Prados, Concepción
A1 Martinez García, Miguel Angel
A1 Rodríguez Hermosa, Juan Luis
A1 de la Rosa, David
A1 Duran, Xavier
A1 Barreiro, Esther
AB We hypothesized that systemic inflammatory and nutritional parameters may differ between male and female patients with non-CF bronchiectasis. In a large patient cohort from the Spanish Online Bronchiectasis Registry (RIBRON), clinical features, systemic inflammatory and nutritional parameters were analyzed in male and female patients with bronchiectasis. Lung function, disease severity using several scores, nutritional status, systemic inflammatory parameters, and multivariate regression analyses were performed to identify differences between male and female patients in the target variables. The number of female patients included in the registry was greater than male patients and they had a less severe disease as measured by all three indices of disease severity, a lower degree of airway obstruction, worse diffusion capacity and airway trapping, better nutritional parameters, and lower levels of inflammatory biomarkers. Multivariate regression analysis evidenced that strong relationships were found between female gender and the following variables: total numbers of leukocytes and neutrophils, hemoglobin, hematocrit, creatinine, and body mass index (BMI). Multivariate regression analyses evidenced that nutritional parameters and inflammatory biomarkers may be reliable indicators of gender-related differences in patients with non-CF bronchiectasis. These findings deserve further attention in follow-up investigations in which the potential predictive value of those biomarkers should be thoroughly explored.
PB MPDI
SN 2227-9059
YR 2021
FD 2021-07-28
LK https://hdl.handle.net/20.500.14352/4649
UL https://hdl.handle.net/20.500.14352/4649
LA eng
NO Instituto de Salud Carlos III (ISCIII)/FEDER
NO Instituto de Salud Carlos III
NO SEPAR 2020
NO ZAMBON-PHARMA
DS Docta Complutense
RD 4 may 2024